Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy
{{output}}
We analyzed the prognostic value of an interim [18F]FDG PET/CT performed after cycle 3 of [177Lu]Lu-PSMA-617 ([177Lu]Lu-PSMA) for patients undergoing therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We retrospectively reviewed the ... ...
